Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement

Scinai regains Nasdaq compliance after 19 days at or above $1.00 per share.

What the company is saying

Scinai Immunotherapeutics Ltd. is announcing that it has received written confirmation from Nasdaq Listing Qualifications that the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company highlights that this closes a previously open compliance matter, which began on March 12, 2026, when Nasdaq notified Scinai of non-compliance after its ADSs traded below $1.00 for 30 consecutive business days. Scinai emphasizes that between August 21 and September 17, 2026, its shares closed at or above $1.00 for 19 consecutive business days, meeting the compliance threshold. CEO Amir Reichman frames this as an important regulatory milestone, expressing appreciation for Nasdaq’s engagement and stating that the company’s focus will now return to commercial execution and NanoAb program advancement. The announcement also reiterates Scinai’s business model, including its immunology therapeutic development and contract development and manufacturing organization (CDMO) operations, as well as its research collaborations with the Max Planck Society and University Medical Center Göttingen. The tone is factual and positive, centering on regulatory closure rather than operational or financial performance.

What the data suggests

The announcement confirms that Scinai’s ADSs closed at or above $1.00 per share for 19 consecutive business days, from August 21 through September 17, 2026, satisfying Nasdaq’s minimum bid price requirement under Rule 5550(a)(2). The compliance process began after a March 12, 2026 notice of non-compliance, triggered by 30 consecutive business days below the $1.00 threshold. Nasdaq’s September 18, 2026 letter formally recognized the regained compliance and closed the matter. No financial performance metrics, revenue figures, or operational KPIs are disclosed in this update. The only quantitative data relate to the compliance process: the $1.00 minimum bid price, the 19-day compliance window, and the relevant dates. The disclosure is complete for its stated purpose but does not provide insight into the company’s financial health, operational progress, or business trajectory beyond regulatory status.

Analysis

The announcement is a factual update regarding Scinai Immunotherapeutics Ltd. regaining compliance with Nasdaq's $1.00 minimum bid price requirement. All key claims are supported by specific dates and figures, and the language is proportionate to the regulatory milestone achieved. The only forward-looking statement is a generic reference to continued focus on commercial execution and program advancement, which is not presented as a near-term catalyst or overhyped projection. There is no mention of large capital outlays, operational expansion, or financial performance, and no attempt to frame the compliance event as a transformative business development. The tone is positive but appropriate for the nature of the news, and there is no evidence of narrative inflation or exaggerated claims.

Risk flags

• ●Regulatory compliance risk remains relevant, as Scinai previously fell below Nasdaq’s minimum bid price and could do so again if market conditions deteriorate. Continued compliance is necessary to avoid future delisting proceedings.
• ●The announcement does not address underlying business fundamentals, such as revenue growth, profitability, or cash reserves. Without financial or operational disclosures, investors cannot assess whether the share price improvement reflects sustainable business progress or short-term market dynamics.
• ●Execution risk persists in Scinai’s core operations, including the advancement of its NanoAb programs and commercial performance of its CDMO business. The announcement provides no update on these fronts, so operational risks remain unquantified.

Bottom line

Scinai Immunotherapeutics Ltd. has resolved its Nasdaq minimum bid price compliance issue, with shares closing at or above $1.00 for 19 consecutive business days and Nasdaq confirming the matter is closed. This removes an immediate regulatory overhang and ensures continued listing, but the announcement does not address business performance, financial health, or operational milestones. Investors now have clarity on the company’s compliance status, but there is no new information on revenue, profitability, or clinical progress. The most important takeaway is that Scinai remains listed and can shift focus back to its core business, but future updates will need to provide substantive operational or financial data to support a more actionable investment thesis.

Announcement summary

(NASDAQ:SCNI) Scinai Immunotherapeutics Ltd. announced that it has received written notification from Nasdaq Listing Qualifications confirming that the company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On March 12, 2026, Nasdaq Staff notified Scinai that the company's American Depositary Shares (ADSs) had failed to maintain a minimum bid price of $1.00 over the prior 30 consecutive business days. In a compliance letter dated September 18, 2026, Nasdaq stated that for the 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai's ADSs was at $1.00 per share or greater. As a result, Nasdaq determined that Scinai had regained compliance with Listing Rule 5550(a)(2) and that the minimum bid price matter is now closed. Amir Reichman, Chief Executive Officer of Scinai, stated that receiving Nasdaq's confirmation closes an important compliance matter for the company and expressed appreciation for Nasdaq Staff's review and engagement. Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on the development of innovative immunology therapies and operates a contract development and manufacturing organization (CDMO). The company is developing its NanoAb platform through research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen. Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

Disagree with this article?